[Results of treatment with peginterferon plus ribavirin in patients with chronic hepatitis C]. / Resultados del tratamiento con peginterferón alfa-2a y ribavirina en pacientes con hepatitis crónica C.

BACKGROUND: The current treatment recommendation for chronic hepatitis C virus infection is the combination of peginterferon and ribavirin for 24 or 48 weeks, depending on the viral genotype. The aim of the therapy is to obtain a sustained virological response. AIM: To report our experience in the treatment of chronic hepatitis C. MATERIAL AND METHODS: Analysis of 52 patients treated between September 2000 and June 2009. Patients with genotype 1 or 5 were treated with peginterferon alpha 2a (180 ug/week) and ribavirin (1000 mg/day for those weighing less than 75 kg and 1200 mg/day for those weighing more than 75 kg) during 48 weeks. Patients with genotypes 2 and 3 were treated for 24 weeks with the same dose of peginterferon and ribavirin 800 mg/day. RESULTS: Viral genotypes 1, 2, 3 and 5 were present in 81, 4, 11 and 4% of patients, respectively. Twenty four patients (46 %), 18 with genotype 1, achieved a sustained viral response. Age was the only variable that influenced the response to treatment. CONCLUSIONS: Approximately half of the patients with chronic hepatitis C, achieve a sustained viral response with peginterferon and ribavirin.

Resultados del tratamiento con peginterferón alfa-2a y ribavirina en pacientes con hepatitis crónica C / Results of treatment with peginterferon plus ribavirin in patients with chronic hepatitis C

Background: The current treatment recommendation for chronic hepatitis C virus infection is the combination of peginterferon and ribavirin for 24 or 48 weeks, depending on the viral genotype. The aim of the therapy is to obtain a sustained virological response. Aim: To report our experience in the treatment of chronic hepatitis C. Material and Methods: Analysis of 52 patients treated between September 2000 and June 2009. Patients with genotype 1 or 5 were treated with peginterferon alpha 2a (180 ug/week) and ribavirin (1000 mg/day for those weighing less than 75 kg and 1200 mg/day for those weighing more than 75 kg) during 48 weeks. Patients with genotypes 2 and 3 were treated for 24 weeks with the same dose of peginterferon and ribavirin 800 mg /day. Results: Viral genotypes 1, 2, 3 and 5 were present in 81, 4, 11 and 4 percent of patients, respectively. Twenty four patients (46 percent), 18 with genotype 1, achieved a sustained viral response. Age was the only variable that infl uenced the response to treatment. Conclusions: Approximately half of the patients with chronic hepatitis C, achieve a sustained viral response with peginterferon and ribavirin.

Encuesta endocrino-ginecológica de la adolescente / Endocrino-ginecologic survey in adolescent female

Se analizó una encuesta en adolescentes de colegios fiscales y particulares de la Quinta Región para determinar la cronología de algunos eventos de la pubertad y la magnitud de algunos problemas endocrino-ginecológicos. El estudio revela que el promedio de edad de aparición de la menarquia en nuestra región es similar a lo referido por autores de países desarrollados, siendo algo más precoz en adolescentes de colegios particulares. Dos tercios de las encuestadas presenta ciclos normales, aunque presentan dismenorrea moderada. Sólo una quinta parte de las encuestadas han consultado al ginecólogo, siendo este porcentaje mayor en adolescentes de colegios particulares. Los datos obtenidos sobre actividad sexual son poco confiables. Se requiere diseñar una metodología para conocer esta importante faceta de la conducta de la mujer adolescente